CLEVELAND- Newly designed chimeric antigen receptor (CAR) T-cells targeting the CD19 antigen are effective in treating adults and children with B-cell malignancies, especially when produced under place-of-care manufacturing which is available at University Hospitals (UH) Seidman Cancer Center. Thats the conclusion of a recent study published in the prestigious journal Nature Communications, detailing two Phase I clinical trials of CAR19 T-cells used to treat patients with relapsed/refractory pediatric B-cell Acute Lymphocytic Leukemia (ALL) or adult B-cell Lymphoma.
Place-of-care manufacturing may improve performance and accessibility by obviating the need to cryopreserve and transport cells to centralized facilities, says study co-author Jane Reese Koc, Cellular Therapy Operations Director at UH Seidman Cancer Center and the National Center for Regenerative Medicine at Case Western Reserve University. The Cellular Therapy Lab is shared by the National Center for Regenerative Medicine, Case Comprehensive Cancer Center and UH Seidman Cancer Center. The results of this study support the safety and efficacy of this approach.
One of the major advantages of this approach is the ability to treat patients significantly quicker than is feasible with commercial CAR T products, adds study co-author David Wald, MD, PhD, Associate Director for Basic Research at the Wesley Center for Immunotherapy at UH Seidman Cancer Center and Associate Professor of Pathology Case Western Reserve University School of Medicine. Commercial products can take three to six weeks to be manufactured. The time savings to treatment with the method is important for these patients that have advanced malignancies. We are working with partners to develop even more rapid methods to shorten the manufacturing method down to a single day.
The Phase I trials involved 31 pediatric and 23 adult patients, located in both Russia and Cleveland. After a median follow-up of 17 months, one-year survival rate of ALL complete responders was 79.2% and median duration of response is 10.2 months. For non-Hodgkin lymphoma (NHL), complete responders one-year survival was 92.9%, and median duration of response has not been reached. The CAR19 T-cells were first tested in cancer cell lines and mouse xenograft models, with positive results.
For NHL, the results were excellent, says hematologist Leland Metheny, MD, who is also involved in these clinical trials at UH Seidman Cancer Center. The results showed they were curative for a significant portion.
Importantly, in the mouse xenograft experiments, fresh CAR19 T-cells produced in the local facility were shown to provide an advantage over cryopreserved cells more commonly used in CAR T applications. Administration of fresh CAR19 T-cells yielded significantly lower tumor burden as compared to dose-matched frozen CAR19 T-cells on study days 11 and 13. On study days 21 and 28, tumors were similarly and potently rejected by both fresh and frozen cell-treated groups. However, fresh cells reduced the tumor burden sooner by eight days, and immediately started reducing the tumor burden, while frozen CAR19 T-cells first permitted tumor growth before controlling growth.
The cells that were given fresh acted much better and more effective in mice in getting rid of the NHL than the frozen cells, Dr. Metheny says. There is something we dont know yet about the impact of the freezing technique that is impacting the CAR T-cells.
In addition to these two clinical trials, Dr. Methenys colleagues at UH Seidman Cancer Center are also conducting a CAR T trial that uses fully human protein one just a handful of sites nationwide to offer this option to patients.
The antibody part of the antigen receptor that were putting on the surface of the T cell is a fully human sequence, says UH Seidman oncologist Benjamin Tomlinson, MD, who is leading this trial. In theory, it may have fewer adverse events, so be slightly safer, while still attacking the same target. The biggest question is whether by not having a foreign component, it may be a little bit more effective in instigations in the signaling. Human to human should connect a little bit better than human to mouse, and it may not generate the type of reactions that we are used to seeing with a regular CAR Ts. So that's what we're exploring. We have opened this humanized CAR T trial and have treated patients with lymphoma and ALL successfully.
In addition, Dr. Wald and colleagues recently reported at the American Society of Hematology meeting on their work identifying potential biomarkers that may help predict outcomes of the patients receiving CAR T-cell therapy.
We hope this will help to design next generation CAR T-cell therapies, he says.
###
About University Hospitals Seidman Cancer Center
UH Seidman Cancer Center is the only freestanding cancer hospital in Northeast Ohio, where all clinicians and staff are dedicated to the prevention, diagnosis and treatment of cancer while researching new and innovative treatment options through clinical trials. Nationally ranked cancer care is also available to patients through the 11-county region at 18 community-based locations. Our UH Seidman specialists make up 14 cancer-specific teams focused on determining integrated care plans tailored to patients needs. UH Seidman Cancer Center is part of the National Cancer Institute (NCI)-designated Case Comprehensive Cancer Center at Case Western Reserve University, one of 51 comprehensive cancer centers in the country. Patients have access to advanced treatment options, ranging from a pioneering stem cell transplant program founded more than 40 years ago and a wide range of immunotherapy to the first and only proton therapy center in northern Ohio for adults and children. Go to UHhospitals.org/Seidman for more information.
About University Hospitals / Cleveland, OhioFounded in 1866, University Hospitals serves the needs of patients through an integrated network of 23 hospitals (including 5 joint ventures), more than 50 health centers and outpatient facilities, and over 200 physician offices in 16 counties throughout northern Ohio.The systems flagship quaternary care, academic medical center, University Hospitals Cleveland Medical Center, is affiliated with Case Western Reserve University School of Medicine, Oxford University and the Technion Israel Institute of Technology. The main campus also includes the UH Rainbow Babies & Children's Hospital, ranked among the top childrens hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the nation, with more than 3,000 active clinical trials and research studies underway. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including Americas Best Hospitals from U.S. News & World Report. UH is also home to 19 Clinical Care Delivery and Research Institutes. UH isone of the largest employers in Northeast Ohio with more than 30,000 employees. Follow UH on LinkedIn, Facebook and Twitter. For more information, visitUHhospitals.org.
Randomized controlled/clinical trial
People
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
- Making Blood Stem Cells on a Microchip: Academic Minute - December 27th, 2022
- Novel detection of stem cell niche within the stroma of limbus in the rabbit during postnatal development | Scientific Reports - Nature.com - August 14th, 2022
- Why Nebraska's U.S. Airmen have filed a lawsuit refusing the COVID-19 vaccine - KETV Omaha - July 27th, 2022
- Hepatic stellate cells in liver development, regeneration, and cancer - July 11th, 2022
- Fasting triggers stem cell regeneration of damaged, old immune system ... - June 13th, 2022
- Columbus man to be one of first to receive transplant via new OhioHealth program - 10TV - April 19th, 2022
- Grayson authorizes more than $1 million for ongoing and new equine research in 2022 - EQUUS Magazine - March 25th, 2022
- Cancer stem cells in glioblastoma - January 20th, 2022
- First-responder cells after heart attack prompt ... - January 20th, 2022
- Riverside Biologics Health Review: At Home "Stem Cells ... - December 24th, 2021
- China-bound Graduate Focused on Global Goals - University of Mary Washington - December 10th, 2021
- Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia -... - December 10th, 2021
- Fruit Cells, Space Bread, and Cultured Meat Cartridges: Deep Space Food Challenge Announces Phase 1 Winners - The Spoon - October 28th, 2021
- Fungi foray: Wild mushrooms are a key part of food chain - Farm and Dairy - August 5th, 2021
- AgeX Therapeutics Inc. (NYSE:AGE) stock surged in the premarket trading session; heres why - Market Globalist - May 13th, 2021
- University Hospitals treats first cancer patient in Ohio with "game changing" CAR T therapy - News 5 Cleveland - May 13th, 2021
- Weekly line: What the new coronavirus variants mean for vaccines, transmission, and more - The Daily Briefing - January 20th, 2021
- Forge Biologics Announces FDA Clearance of Investigational New Drug Application for Phase 1/2 Clinical Trial (RESKUE) of FBX-101 Gene Therapy for... - January 9th, 2021
- The Rise of Steve Sarkisian ... And the Decline of the Man Who Got Him Here - Sports Illustrated - January 9th, 2021
- Raleigh man delivers stem cells to patients around the world - WRAL.com - November 28th, 2020
- A real life Superman celebrates 5 years of survival from one of the deadliest cancers - Newswise - November 28th, 2020
- The Museum That Fell From the Sky | History - Air & Space Magazine - November 28th, 2020
- A Detroit Lions VP tries to avoid wasting her daughter from uncommon illness - The Shepherd of the Hills Gazette - November 28th, 2020
- US biotechnology company races to get its COVID-19 therapeutic approved for access, which has previously shown positive results in severely ill... - November 5th, 2020
- STEM CELLS - Regenerative Medicine Institute of Ohio - October 18th, 2020
- FDA Grants Orphan Drug Designation to Novel Bcl-2 inhibitor in CLL - Targeted Oncology - September 9th, 2020
- Breastfeeding 'even better than previously thought' - The Irish News - The Irish News - June 29th, 2020
- Regenerative Therapy Options for Horses With Osteoarthritis - TheHorse.com - June 12th, 2020
- Why Do Some People Get Sick All the Time, While Others Stay in Freakishly Good Health? - Discover Magazine - June 12th, 2020
- How safe are Ohio summer fun activities amid the coronavirus threat? The Wake Up for Friday, May 29, 2020 - cleveland.com - May 31st, 2020
- Kenneth Wallace Promoted to Full Professor at Clarkson University - Clarkson University News - May 31st, 2020
- ODDS AND ENDS: Melonheads and other offbeat offerings - Toronto Sun - May 31st, 2020
- OHIO researchers win grant to study treatment for possible fatal complications of COVID-19 - Huntington Herald Dispatch - May 8th, 2020
- Coronavirus Today: We're starting to reopen - Los Angeles Times - May 8th, 2020
- COMMENTARY || Pseudoscience and COVID-19we've had enough already - Folio - University of Alberta - May 3rd, 2020
- This Week in Green Tech: STEM Lessons, Solar Power and the Coronavirus, and More - ENGINEERING.com - May 3rd, 2020
- AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure - BioSpace - February 7th, 2020
- Tune in Tonight: Oscar-nominated The Cave debuts on National Geographic - St. Augustine Record - January 25th, 2020
- Best Stem Cell Therapy Treatment in Cincinnati, Ohio ... - November 28th, 2019
- Time to Try Again: Gene-Based Therapy for Neurodegeneration - Alzforum - November 28th, 2019
- NIA Mourns the Loss of Dr. Huber Warner - National Institute on Aging - November 13th, 2019
- Research Roundup: Genomic Dark Matter Mutation and More - BioSpace - October 23rd, 2019
- Stem Cell Treatment Lima | Orthopaedic Institute of Ohio - September 10th, 2019
- Regenerative Therapy in Northeast Ohio | Ohio Therapy Centers - September 9th, 2019
- Stem cell therapy now available in central Ohio! - May 30th, 2019
- Stem Cell Therapy Clinic in Cleveland, Ohio - March 26th, 2019
- Massages & Treatments | Day Spa on Lake Erie in Ohio | The ... - March 10th, 2019
- *NEW* Regenerative Stem Cell Therapy | Ohio Therapy Centers - December 7th, 2018
- Stem Cell Therapy | Ohio Stem Cell - November 5th, 2018
- Ohio Stem Cell Treatment Center of Cleveland (Beachwood ... - November 3rd, 2018
- Conjoined twins - Wikipedia - September 20th, 2018
- Government website steers patients to unproven medical treatments - MyAJC - September 2nd, 2017
- Modern Health & Wellness of Lima institutes regenerative stem cell therapy - Lima Ohio - September 2nd, 2017
- Salk faces 'daunting' need for money despite big success with ... - The San Diego Union-Tribune - August 26th, 2017
- 'Nanotransfection' Turns Animal Skin into Blood Vessels and Brain ... - Medical Device and Diagnostics Industry - August 26th, 2017
- This Chip Uses Electricity to Reprogram Cells for Healing - Singularity Hub - August 25th, 2017
- This year's freshman class at Misericordia University is third largest in school history - The Dallas Post - August 25th, 2017
- Nanochip Could Heal Injuries or Regrow Organs with One Touch - NewsFactor Network - August 18th, 2017
- Wild new microchip tech could grow brain cells on your skin - CNET - August 8th, 2017
- Researchers explore possible alternative to knee replacement - Scope (blog) - August 5th, 2017
- Jackson Twp.'s Emmie Wanzer loves her new wheelchair swing provided by Wishes Can Happen Wanzer - Canton Repository - July 4th, 2017
- Scientists Discover That Fasting Triggers Stem Cell ... - November 23rd, 2016
- Stem-Cells | The Institute for Applied & Professional Ethics - November 18th, 2016
- Stem Cell Transplant Program - Cleveland, Ohio - October 17th, 2016
- Update: Ohio Stem Cell Study Recruiting People with MS ... - October 17th, 2016
- National Center For Regenerative Medicine - October 17th, 2016
- Stem-cell niche - Wikipedia, the free encyclopedia - October 19th, 2015
- Alex Potoczak of Ohio Praises Umbilical Stem Cell Research ... - July 2nd, 2015
- Dr. Foglietti | Ohio Stem Cell Treatment Center of Cleveland - April 27th, 2015
- Taubman Institute Receives $3 Million Wexner Gift to Support Emerging Physician-Researchers - April 3rd, 2015
- Morgan's Fund Launches Necrotizing Enterocolitis (NEC) Podcast Series: Premiere Features Dr. Gail Besner - March 24th, 2015
- Ohio Stem Cell Knee Arthritis Treatment-Regenexx - February 23rd, 2015
- We Were Promised Space Lasers: The State of the Union's Biggest Fibs - January 21st, 2015
- We Were Promised Space Lasers: State of the Union's Biggest Fibs - January 20th, 2015
- We Were Promised Space Lasers: The State of the Union's Big Fibs - January 17th, 2015
- 'Unprecedented': Drug May Help Heal Damaged Spines - December 4th, 2014
- New DNA discovery could lead to chromosome therapies in the future - November 19th, 2014
- Tiny Stomachs Grown in the Lab - October 31st, 2014
- Stem Cells Used to Grow Mini-Stomachs Seeking Treatments - October 30th, 2014
- Scientists build 'mini-stomachs' in lab - October 30th, 2014